SOPHIA ANTIPOLIS, France – October 09, 2024 │ Amidst the rapidly evolving landscape of medical biotechnology, especially in the therapeutic RNA sector, groundbreaking advances continue to reshape the field. The latest release of our Therapeutic mRNA patent monitor delivers comprehensive insights, underscoring a notable acceleration in intellectual property developments, pushing the boundaries of RNA-based treatments and vaccines. Our detailed analysis shines a spotlight on the thriving innovation engine and recognizes pivotal contributors driving these advancements.
Let’s take a closer look
In the spotlight of our analysis, our latest monitoring report reveals a significant uptick in intellectual property activity within the therapeutic RNA field. In Q3 2024 alone, 200 new patent applications were published, reflecting a marked increase from the 120 applications filed during the same period in 2023. Notably, industry leaders BioNTech, Moderna, and Pfizer continue to drive innovation, with BioNTech leading the pack with 16 new applications, followed by Moderna with 9, and Pfizer with 8. In comparison, Q3 2023 saw Moderna, BioNTech, and Pfizer file only 7, 6, and 1 new applications, respectively—underscoring the growing momentum in mRNA technology.
In addition, our monitoring services have identified 54 new patents granted within key jurisdictions (US, EP, JP, KR) during Q3 2024. Moderna further strengthened its intellectual property portfolio, securing 7 newly granted patents. The majority of these grants were concentrated in the US (26 patents), followed by Japan (15) and Europe (9), see figure 1.
Figure 1: Q3 2023 vs Q3 2024 regarding new patent applications.
This remarkable growth trajectory reflects the burgeoning demand for innovative therapeutic solutions and highlights the commitment of these influential entities to advancing their R&D capabilities and intellectual capital.
Why subscribe to this monitor?
A patent monitor stands as a strategic tool for businesses aiming to maintain their competitive edge in cutting-edge fields like mRNA therapeutics. Our monitoring services deliver timely, curated patent intelligence, enabling organizations to track technological advancements, uncover potential collaborations, and safeguard their inventions against infringement risks. By subscribing to our bespoke IP monitoring solutions, companies gain access to analytical insights that facilitate informed decision-making. This empowers enterprises to strategically navigate the complexities of the intellectual property landscape, ultimately driving growth and innovation in their respective domains.
For more detailed insights into these developments and how they may impact your business, please contact us.
Press contact
contact@knowmade.fr
Le Drakkar, 2405 route des Dolines, 06560 Valbonne Sophia Antipolis, France
www.knowmade.com
About KnowMade
KnowMade is a technology intelligence and IP strategy consulting company specialized in analyzing patents and scientific publications. The company helps innovative companies, investors, and R&D organizations to understand competitive landscape, follow technological evolutions, reduce uncertainties, and identify opportunities and risks in terms of technology and intellectual property.